188 related articles for article (PubMed ID: 27266878)
1. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China.
Xin XX; Guan XD; Shi LW
Orphanet J Rare Dis; 2016 Jun; 11(1):74. PubMed ID: 27266878
[TBL] [Abstract][Full Text] [Related]
2. The availability and affordability of orphan drugs for rare diseases in China.
Gong S; Wang Y; Pan X; Zhang L; Huang R; Chen X; Hu J; Xu Y; Jin S
Orphanet J Rare Dis; 2016 Feb; 11():20. PubMed ID: 26920579
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting catastrophic health expenditure and impoverishment from medical expenses in China: policy implications of universal health insurance.
Li Y; Wu Q; Xu L; Legge D; Hao Y; Gao L; Ning N; Wan G
Bull World Health Organ; 2012 Sep; 90(9):664-71. PubMed ID: 22984311
[TBL] [Abstract][Full Text] [Related]
5. The effect of NCMS on catastrophic health expenditure and impoverishment from tuberculosis care in China.
Zhou C; Long Q; Chen J; Xiang L; Li Q; Tang S; Huang F; Sun Q; Lucas H; Huan S
Int J Equity Health; 2016 Oct; 15(1):172. PubMed ID: 27756368
[TBL] [Abstract][Full Text] [Related]
6. Protecting patients with cardiovascular diseases from catastrophic health expenditure and impoverishment by health finance reform.
Sun J; Liabsuetrakul T; Fan Y; McNeil E
Trop Med Int Health; 2015 Dec; 20(12):1846-54. PubMed ID: 26426679
[TBL] [Abstract][Full Text] [Related]
7. Inequalities in Household Catastrophic Health Expenditure and Impoverishment Associated With Noncommunicable Diseases in Chi Linh, Hai Duong, Vietnam.
Kien VD; Minh HV; Ngoc NB; Phuong TB; Ngan TT; Quam MB
Asia Pac J Public Health; 2017 Jul; 29(5_suppl):35S-44S. PubMed ID: 28719772
[TBL] [Abstract][Full Text] [Related]
8. Trends and socio-economic disparities in catastrophic health expenditure and health impoverishment in China: 2010 to 2016.
Zhao Y; Oldenburg B; Mahal A; Lin Y; Tang S; Liu X
Trop Med Int Health; 2020 Feb; 25(2):236-247. PubMed ID: 31713972
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges.
Qiao L; Liu X; Shang J; Zuo W; Xu T; Qu J; Jiang J; Zhang B; Zhang S
Orphanet J Rare Dis; 2022 Sep; 17(1):352. PubMed ID: 36088349
[TBL] [Abstract][Full Text] [Related]
10. Socioeconomic inequalities in catastrophic health expenditure and impoverishment associated with non-communicable diseases in urban Hanoi, Vietnam.
Kien VD; Van Minh H; Giang KB; Dao A; Tuan LT; Ng N
Int J Equity Health; 2016 Oct; 15(1):169. PubMed ID: 27737663
[TBL] [Abstract][Full Text] [Related]
11. Determinants and Equity Evaluation for Health Expenditure Among Patients with Rare Diseases in China.
Xin XX; Zhao L; Guan XD; Shi LW
Chin Med J (Engl); 2016 Jun; 129(12):1387-93. PubMed ID: 27270531
[TBL] [Abstract][Full Text] [Related]
12. Non-evidence-based policy: how effective is China's new cooperative medical scheme in reducing medical impoverishment?
Yip W; Hsiao WC
Soc Sci Med; 2009 Jan; 68(2):201-9. PubMed ID: 19019519
[TBL] [Abstract][Full Text] [Related]
13. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
Guan X; Zhang J; Man C; Ni B; Shi L
J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
[TBL] [Abstract][Full Text] [Related]
14. Catastrophic health expenditure and impoverishment in Turkey.
Yardim MS; Cilingiroglu N; Yardim N
Health Policy; 2010 Jan; 94(1):26-33. PubMed ID: 19735960
[TBL] [Abstract][Full Text] [Related]
15. Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis.
Álvarez-Hernández E; Peláez-Ballestas I; Boonen A; Vázquez-Mellado J; Hernández-Garduño A; Rivera FC; Teran-Estrada L; Ventura-Ríos L; Ramos-Remus C; Skinner-Taylor C; Goycochea-Robles MV; Bernard-Medina AG; Burgos-Vargas R
Reumatol Clin; 2012; 8(4):168-73. PubMed ID: 22704914
[TBL] [Abstract][Full Text] [Related]
16. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
17. Catastrophic Health Expenditure and Impoverishment from Non-Communicable Diseases: A comparison of Private and Public Health Facilities in Ekiti State, Southwest Nigeria.
Ipinnimo TM; Durowade KA
Ethiop J Health Sci; 2022 Sep; 32(5):993-1006. PubMed ID: 36262712
[TBL] [Abstract][Full Text] [Related]
18. Household catastrophic healthcare expenditure and impoverishment due to rotavirus gastroenteritis requiring hospitalization in Malaysia.
Loganathan T; Lee WS; Lee KF; Jit M; Ng CW
PLoS One; 2015; 10(5):e0125878. PubMed ID: 25941805
[TBL] [Abstract][Full Text] [Related]
19. A Tale of Transition: Trends of Catastrophic Health Expenditure and Impoverishment in Urban China, 1986-2009.
Song Z; Zhu Y; Zou H; Fu H; Yip W
Health Syst Reform; 2020 Dec; 6(1):e1836731. PubMed ID: 33253047
[TBL] [Abstract][Full Text] [Related]
20. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
